Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Introduction: Ayahuasca is a plant-based decoction native to Amazonia, where it has a long history of use in traditional medicine. Contemporary ritual use of ayahuasca has been expanding throughout the world for mental health purposes, and for spiritual and personal growth. Although researchers have been conducting clinical trials and observational studies reporting medical and psychological benefits, most of these do not report ayahuasca’s immediate or medium-term adverse effects, so these are underrepresented in the literature. With the expansion of ayahuasca ceremonies from their traditional contexts to countries around the world, there is an important public health question regarding the risk/benefit balance of its use. Methods: We used data from an online Global Ayahuasca Survey (n = 10,836) collected between 2017 and 2019 involving participants from more than 50 countries. Principal component analysis was performed to assess group effects. Logistic regression analysis was performed to test for adverse effects associated with history of ayahuasca use, clinical, context of use and spiritual effect variables. Results: Acute physical health adverse effects (primarily vomiting) were reported by 69.9% of the sample, with 2.3% reporting the need for subsequent medical attention. Adverse mental health effects in the weeks or months following consumption were reported by 55.9% of the sample, however, around 88% considered such mental health effects as part of a positive process of growth or integration. Around 12% sought professional support for these effects. Physical adverse effects were related to older age at initial use of ayahuasca, having a physical health condition, higher lifetime and last year ayahuasca use, having a previous substance use disorder diagnosis, and taking ayahuasca in a non-supervised context. Mental health adverse effects were positively associated with anxiety disorders; physical health conditions; and the strength of the acute spiritual experience; and negatively associated with consumption in religious settings. Conclusions: While there is a high rate of adverse physical effects and challenging psychological effects from using ayahuasca, they are not generally severe, and most ayahuasca ceremony attendees continue to attend ceremonies, suggesting they perceive the benefits as outweighing any adverse effects. Knowing what variables might predict eventual adverse effects may serve in screening of, or providing additional support for, vulnerable subjects. Improved understanding of the ayahuasca risk/benefit balance can also assist policy makers in decisions regarding potential regulation and public health responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a global survey involving 10,836 participants, 2.3% reported requiring medical support following ayahuasca use (32).”
From Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol (2025) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, bioavailability of the psychoactive compound DMT varies greatly between and within individuals due to the excessive metabolic first-pass degradation by the MAO enzyme associated with oral ingestion of ayahuasca, which potentially leads to unexpected intensities, overwhelming experiences, and thereby increases psychological risks (48).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nausea and vomiting are common during ayahuasca sessions (32)”
From Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol (2025) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“In a global ayahuasca survey, 42% of participants reported–mostly transient – challenging emotional-cognitive adverse effects (48) such as feeling disconnected or alone (21%).”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Ultra-Brief Screening Scale for Anxiety and Depression: The PHQ–4
Kroenke, K., Spitzer, R. L., Williams, J. B. W., & Löwe, B. (2009) · Psychosomatics · doi:10.1016/s0033-3182(09)70864-3 · Cited by 4,261
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Self-citationOsório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Sanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Self-citationRiba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390 · cited 2×
“75mg/DMT/kg), and high (1mg/DMT/kg) doses of ayahuasca [40, 41], subjects scored active doses higher than a placebo in terms of the Visual Analogue Scales “liking,” and the ayahuasca was well tolerated.”
BackgroundBouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313 · cited 2×
“[31, 64, 65] and both prospective longitudinal studies, e.”
ResultSelf-citationRiba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J. (2001) · Psychopharmacology · doi:10.1007/s002130000606 · Cited by 303 · cited 2×
“75mg/DMT/kg), and high (1mg/DMT/kg) doses of ayahuasca [40, 41], subjects scored active doses higher than a placebo in terms of the Visual Analogue Scales “liking,” and the ayahuasca was well tolerated.”
BackgroundNeuropharmacology of N,N-dimethyltryptamine
Carbonaro, T. M., & Gatch, M. B. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.016 · Cited by 268 · cited 8×
“Classical hallucinogens, including DMT [66], bind with 5-HT2A receptors, inducing the release of glutamate, which, theoretically, may eventually lead to convulsions and seizures in neurologically vulnerable individuals.”
BackgroundInfluentialRisk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.
Gable, R. S. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01652.x · Cited by 244 · cited 4×
“However, this has previously been estimated to occur less frequently than in the general population [48].”
BackgroundInfluential
Research works printed but not linked: 2
- C Sánchez-Avilés, 2015, Ayahuasca: From the Amazon to the global village
- JC Bouso, 2021, Ayahuasca Technical Report.
Cited by
Extended difficulties following the use of psychedelic drugs: A mixed methods study
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., Luke, D., Michelle, K., & Prideaux, E. (2023) · PLOS ONE · doi:10.1371/journal.pone.0293349 · Cited by 185
Lutkajtis, A., & Evans, J. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00232 · Cited by 70
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., et al. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.146 · Cited by 75
“Structural differences in the ACC and PCC shown by Bouso et al. 95 may explain the preservation of neuropsychological function.”
BackgroundInfluentialSelf-citationEgger, K., Aicher, H., Cumming, P. D., & Scheidegger, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05353-6 · Cited by 46
“On the other hand, challenging psychedelic experiences are common (55.9%), with adverse psychological reactions typically subsiding within a few days; however, 12% of such individuals sought additional professional support [124, 125].”
BackgroundInfluentialSelf-citationRobinson, O. C., Evans, J., Luke, D. P., McAlpine, R. G., Sahely, A., Fisher, A. M., Sundeman, S., Argyri, E. K., Murphy-Beiner, A., Michelle, K., et al. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1369715 · Cited by 36
“A survey by Bouso et al. (2022) found that 11.9% of ayahuasca users eventually sought professional mental health assistance for adverse effects.”
BackgroundInfluentialLake, S., & Lucas, P. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0002 · Cited by 40
“33,34 The narrative practice of finding value in the challenging aspects of a psychedelic experience is thought to serve as a coping and integration mechanism.”
Aicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1302559 · Cited by 33
“…DMT varies greatly between and within individuals due to the excessive metabolic first-pass degradation by the MAO enzyme associated with oral ingestion of ayahuasca, which potentially leads to unexpected intensities, overwhelming experiences, and thereby increases psychological risks (48).”
BackgroundInfluentialSelf-citationZeifman, R. J., Kettner, H., Pagni, B. A., Mallard, A. J., Roberts, D. E., Erritzøe, D., Ross, S., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-40856-5 · Cited by 37
Dornbierer, D. A., Marten, L., Mueller, J., Aicher, H. D., Mueller, M. J., Boxler, M., Kometer, M., Kosanic, D., von Rotz, R., Puchkov, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1246892 · Cited by 32
Self-citationPerkins, D., Ruffell, S., Day, K., Rubiano, D. P., & Sarris, J. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.879221 · Cited by 54
Self-citationWhen the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research
Jacobs, E., Murphy-Beiner, A., Rouiller, I., Nutt, D. J., & Spriggs, M. J. (2023) · Neuroethics · doi:10.1007/s12152-023-09536-z · Cited by 35
Calder, A. E., & Hasler, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.091 · Cited by 28
Friedberg, L. M., Sen, A. K., Nguyen, Q., Tonucci, G. P., Hellwarth, E. B., Gibbons, W. J., & Jones, J. A. (2023) · Metabolic Engineering · doi:10.1016/j.ymben.2023.05.006 · Cited by 27
Robinson, O. C., Evans, J., McAlpine, R. G., Argyri, E. K., & Luke, D. P. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00420 · Cited by 23
Ayahuasca and Dimethyltryptamine Adverse Events and Toxicity Analysis: A Systematic Thematic Review
White, E., Kennedy, T., Ruffell, S., Perkins, D., & Sarris, J. J. (2024) · International Journal of Toxicology · doi:10.1177/10915818241230916 · Cited by 27
“65 Generally, these were mild and transient and considered to be part of a positive process of psychological growth or integration of the psy-chedelic experience.”
BackgroundSelf-citationCowley‐Court, T., Chenhall, R. D., Sarris, J. J., Bouso, J. C., Tófoli, L. F., Opaleye, E. S., Schubert, V., & Perkins, D. (2023) · Psychoactives · doi:10.3390/psychoactives2020014 · Cited by 26
“4% of 7839 survey participants from the same broader study (the Global Ayahuasca Project) reported experiencing mental and emotional challenges in the weeks and months after drinking ayahuasca [4].”
BackgroundResultInfluentialSelf-citationPerkins, D., Opaleye, E. S., Bouso, J. C., Tófoli, L. F., Sarris, J. J., Schubert, V., Ruffell, S., & Šimonová, H. (2023) · Psychoactives · doi:10.3390/psychoactives2040017 · Cited by 22
“However, psychological side effects in the weeks after consumption are not uncommon, and although typically transient and mild, for a small proportion they can be enduring and require professional mental health support [22].”
Self-citationEffects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study
Aday, J. S., Bloesch, E. K., Davis, A. K., Domoff, S. E., Scherr, K. C., Woolley, J. D., & Davoli, C. C. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2312980 · Cited by 19
“It is not uncommon for users to purge or experience digestive discomfort during the onset of the drug, and some consider these effects to be essential aspects of the healing/cleansing process (Bouso et al. 2022; Osório et al., 2015).”
BackgroundAyahuasca: Pharmacology, Safety, and Therapeutic Effects
SANTOS, R. G. D., & Hallak, J. E. C. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009585330.005 · Cited by 24
Traumatic Psychedelic Experiences
Calder, A. E., Diehl, V. J., & Hasler, G. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_579 · Cited by 21
Griffiths, R. R., Jesse, R., Richards, W. A., Johnson, M. W., Sepeda, N. D., Bossis, A. P., & Ross, S. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2023.0044 · Cited by 18
“32,33 44 While psychedelics continue to be used in some Indigenous religious contexts, they are generally not used within major world religions (e.g., Hinduism, Judaism, Buddhism, Christianity, Islam).”
Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study
Simon, G., Tadmor, N., Skragge, M., Evans, J., & Robinson, O. C. (2025) · Scientific Reports · doi:10.1038/s41598-025-26198-4 · Cited by 16
Psychedelic Therapy: A Primer for Primary Care Clinicians—N,N-Dimethyltryptamine and Ayahuasca
Shinozuka, K., Tabaac, B. J., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001725 · Cited by 21
“57 The MAO inhibitors in ayahuasca cause high levels of unmetabolized serotonin to accumulate in the gut.”
BackgroundEgger, K., Redondo, J. J., Müller, J., Dornbierer, J., Smallridge, J. W., Aicher, H., Meling, D., Müller, P., Kost, J., Puchkov, M., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117908 · Cited by 15
Self-citationElfrink, S., & Bergin, L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1528253 · Cited by 20
Fonseca, A. M., SANTOS, R. G. D., de Medeiros, L. S., Veiga, T. A. M., Cassas, F., Bruniera, C. P., Rossi, G. N., Bouso, J. C., Hallak, J. E. C., Santos, F. P., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01817-9 · Cited by 17
Self-citationPsychedelic group-based integration: ethical assessment and initial recommendations
Cheung, K., Propes, C., Jacobs, E., Earp, B. D., & Yaden, D. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357678 · Cited by 14
“…Jose Carlos Bouso and colleagues found in the Global Ayahuasca Survey that one of the most frequently reported mental health adverse effects was feeling disconnected or alone (21%), as did a study of challenging experiences using classic psychedelics (Bouso et al., 2022; Simonsson et al., 2023).”
The Epidemiology of Psychedelic Use Among United States Military Veterans
Davis, A. K., Bates, M. J., Lund, E. M., Sepeda, N. D., Levin, A. W., Armstrong, S. B., Koffman, R. L., Hooyer, K., & Yehuda, R. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2401977 · Cited by 12
“…retreat settings, rapport with session facilitators has been shown to mediate positive acute experiences and long-term outcomes (Kettner et al. 2021), and the use of psychedelics in non-supervised, non-traditional contexts has been associated with more adverse outcomes (Bouso et al. 2022).”
Berlowitz, I., Pesantes, M. A., Palacios, C. C., Martin-Söelch, C., Wolf, U., & Maake, C. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0003912 · Cited by 15
Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis
van der Heijden, K. V., Otto, M. E., Schoones, J. W., van Esdonk, M. J., Borghans, L. G. J. M., van Hasselt, J. G. C., van Gerven, J., & Jacobs, G. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01450-8 · Cited by 13
“However, a major drawback of ayahuasca is the addition of harmines, used to prevent the rapid metabolism of DMT by monoamine oxidase A (MAO-A), which cause untoward side effects, such as nausea, vomiting, and diarrhoea [12].”
Gearin, A. K. (2023) · Social Science & Medicine · doi:10.1016/j.socscimed.2023.116171 · Cited by 11
Mueller, M. J., Aicher, H., Dornbierer, D., Marten, L., Suay, D., Meling, D., Elsner, C., Wicki, I. A., Müller, J., Poetzsch, S. N., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf001 · Cited by 14
Self-citationOlofsson, M., Osika, W., Goldberg, S. B., Hendricks, P. S., Petrović, P., White, T. J. H., Stenfors, C. U. D., Chaturvedi, S., & Simonsson, O. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105105 · Cited by 12
“It is also possible that some individuals may interpret the adverse mental health effects of psychedelic use as part of a positive therapeutic process, as observed in previous research (Bouso et al., 2022; Gashi et al., 2021).”
Extended Difficulties Following the Use of Psychedelic Drugs: A Mixed Methods StudyPreprint
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., & McAlpine, R. G. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4487243 · Cited by 12
Do classic psychedelics increase the risk of seizures? A scoping review
Soto-Angona, Ó., Fortea, A., Fortea, L., Martínez-Ramírez, M., Santamarina, E., Gil-López, F., Knudsen, G. M., & Oña, G. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.05.002 · Cited by 9
Childhood trauma, challenging experiences, and posttraumatic growth in ayahuasca use
Cassidy, E. K., Healy, C. J., Henje, E., & D'Andrea, W. M. (2024) · Drug Science Policy and Law · doi:10.1177/20503245241238316 · Cited by 9
“…physical and psychological symptoms, commonly occur during and following ayahuasca experiences and are reported by up to 17.5% of fi rst-time ayahuasca users (Barbosa et al., 2012; Bouso et al., 2022; Durante et al., 2020; Gómez-Sousa et al., 2021; Haijen et al., 2018; Halpern et al., 2008).”
InfluentialWilkes, R., Roberts, D. M., Liknaitzky, P., & Brett, J. (2024) · Clinical Toxicology · doi:10.1080/15563650.2024.2346612 · Cited by 9
Bassi, M., Bilel, S., Tirri, M., Corli, G., Rosa, F. D., Gregori, A., Alkilany, A. M., Rachid, O., Roda, E., Zauli, G., et al. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06526-8 · Cited by 9
“…and vomiting, disorientation, tachycardia, hypertension, confusion, headache, and speech difficulties, basing on information reported by consumers (Erowid 2015a, b, c; Psychonautwiki 2022, 2023a, b) and case reports (Smolinske et al. 2005; Muller 2004; Heise and Brooks 2017; Bouso et al. 2022).”
BackgroundEMBARK Psychedelic Therapy for Depression: A New Approach for the Whole Person
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Hong Kong Poison Information Centre: Annual report 2021
Chow, T. Y. A., Chan, C. K., Ng, S. H., & Tse, M. L. (2024) · Hong Kong Journal of Emergency Medicine · doi:10.1002/hkj2.12051 · Cited by 8
Ayahuasca ceremony leaders’ perspectives on special considerations for eating disorders
Williams, M., Miller, A. K., & Lafrance, A. (2023) · Eating Disorders · doi:10.1080/10640266.2023.2271201 · Cited by 8
“…the scientific literature relevant to the potential physical, emotional, and spiritual risks of drinking ayahuasca for the general population (e.g., Bouso et al., 2022; Dobkin de Rios & Rumrrill, 2008; Frecska, 2007; Gómez-Sousa et al., 2021; Ray & Lassiter, 2016; Ruffell et al., 2020; Trichter,…”
BackgroundRojas‐Hernández, J., Borkel, L. F., Hernández, D. J. Q., Santana, Á., & Henríquez‐Hernández, L. A. (2024) · Current Psychology · doi:10.1007/s12144-024-07017-x · Cited by 8
“According to data from an online Global Ayahuasca Survey, with almost 11,000 participants, acute adverse effects (primarily vomiting) were reported by 69.9% of the sample, a lower percentage than that observed in our series (Bouso et al., 2022 ).”
InfluentialSabucedo, P., Andión, O., Neimeyer, R. A., Soto-Angona, O., Javkin, J., Haro, J. M., Farré, M., & González, D. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1484736 · Cited by 6
Self-citationAndersen, K. A. A., Holmøy, B., Kvam, T.-M., & Johnson, M. W. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.05.062 · Cited by 6
Al-Imam, A., Motyka, M. A., Hoffmann, B., Magowska, A. M., & Michalak, M. (2023) · Pharmaceuticals · doi:10.3390/ph16060831 · Cited by 7
“Interestingly, however, for most trial participants (88%), these sensations were still considered part of a positive process conducive to improving their psychological functioning [54].”
BackgroundThe Psychedelic Renaissance: A Catholic Perspective
Carroll, T. (2024) · The Linacre Quarterly · doi:10.1177/00243639241274818 · Cited by 5
“However, one group characterizing adverse effects of ayahuasca (the active ingredient of which is DMT 11 ) reported that 14.9% of respondents to an online survey indicated they had experienced, “ Feeling ‘ energetically attacked ’ or a harmful connection with a ‘ spirit world ’” (Bouso et al. 2022).”
InfluentialDavid, J., Berkovich‐Ohana, A., & Dor‐Ziderman, Y. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06792-0 · Cited by 6
“This aligns with studies showing that a certain percentage of individuals undergoing psychedelic experiences develop worsened mental health (Bouso et al. 2022; Dos Santos et al. 2017; Mar-rocu et al. 2024).”
McAlpine, R. G., Utanğaç, M., Kuc, J., Pankhurst, H., Sellers, A., Kraft, D., Litchy, A., Gupta, N. E., Timmermann, C., Kamboj, S. K., et al. (2026) · Mindfulness · doi:10.1007/s12671-026-02957-w · Cited by 6
Guidelines for Establishing Safety in Ayahuasca and Ibogaine Administration in Clinical Settings
Rocha, J. M., Reis, J. A. S., Rossi, G. N., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2023) · Psychoactives · doi:10.3390/psychoactives2040024 · Cited by 6
“A recent study survey based on more than 10,836 subjects found that 60% of the sample reported some kind of mental adverse event, but 88% of them considered that event as part of a positive growth process [20].”
BackgroundSelf-citationDrug-induced psychosis following use of Ayahuasca: a presentation to forensic psychiatric services
Baker, M., & O'Shea, C. I. (2024) · BMJ Case Reports · doi:10.1136/bcr-2024-260648 · Cited by 4
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice
Hu, X., Gorman, I., & Nielson, E. M. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_529 · Cited by 4
Soto-Angona, Ó., Andión, Ó., Sabucedo, P., Neimeyer, R. A., Haro, J. M., Javkin, J., Farré, M., & González, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-13251-5 · Cited by 5
“The incidence of minor adverse effects in the experimental group is aligned with prior research on ayahuasca use 32,33 .”
Self-citationKruger, D. J., Mersereau, G., Sullivan, A., Barron, J., Herberholz, M., Pouyan, N., Aday, J. S., & Boehnke, K. F. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01337-2 · Cited by 4
“Adverse mental health effects included feelings of loneliness, nightmares, anxiety, uncontrollable worrying, and derealization; around 12% sought professional support afterward [25].”
InfluentialPersistent Altered States: Psychological Treatment of Psychedelic Adverse Effects
Holmøy, B., & Andersen, K. A. A. (2025) · Tidsskrift for Norsk psykologforening · doi:10.52734/hgsn7664 · Cited by 4
Griffin, C., & Knight, A. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00333 · Cited by 6
“Bouso et al. (2022) investigated the adverse effects associated with ayahuasca use and reported that while vomiting was reported in 69.9% of participants and general adverse mental health effects in 55.9%, 88% of the sample considered these as part of a positive process of growth and integration.”
BackgroundInfluentialPerspectives of Psychotherapists Regarding Psychedelic Assisted Therapy
Kinahan, S. P., & Wilson, E. J. (2025) · Counselling and Psychotherapy Research · doi:10.1002/capr.12881 · Cited by 5
Sznitman, S. R., Behar, Y. A., Dicker‐Oren, S. D., Shochat, T., Meiri, D., Butto, N., Roe, D., & Bernstein, A. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06704-8 · Cited by 8
“Observational research has found that such difficult acute experiences are commonly interpreted by participants as beneficial to their mental well-being (Carbonaro et al. 2016 ; Johns-tad 2021; Gashi et al. 2021; Bouso et al. 2022; Lake and Lucas 2023).”
InfluentialThe psychedelic-peptide paradox: a hormetic hypothesis
Carter, C. S. (2025) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2025.100303 · Cited by 4
Psychedelics and the future evolution of humanity
Winkelman, M. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00464 · Cited by 4
Day, J. K., & Grooff, M. T. (2025) · Contemporary Drug Problems · doi:10.1177/00914509251371749 · Cited by 4
“…or claims to the effect that recreational users are highly likely to pose a hazard to the health and safety of others (Bender & Hellerstein, 2022; Bouso et al., 2022; Bremler et al., 2023; Carhart-Harris & Nutt, 2013; Dos Santos et al., 2017; Durante et al., 2021; Evans et al., 2023;…”
InfluentialClinical pharmacology of ayahuasca: potential applications and future considerations
Guerra, L. T. L., Dias, I. C. D. S., Hallak, J. E. C., & SANTOS, R. G. D. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2577726 · Cited by 3
Ayahuasca ceremonies: set and setting features across Italy and Colombia
Ambrosini, F., Pariset, L., & Biolcati, R. (2023) · Drugs Habits and Social Policy · doi:10.1108/dhs-06-2023-0021 · Cited by 4
Lima, G., Soares, C., Teixeira, M., & Castelo-Branco, M. S. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16264 · Cited by 3
Beyond prohibition: A public health analysis of naturalistic psychedelic use
Haden, M., Paschall, S. A., & Woods, B. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00450 · Cited by 6
Äbelö, A., Smallridge, J. W., von Rotz, R., Dornbierer, D., Egger, K., Ashton, M., & Scheidegger, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118329 · Cited by 6
Self-citationBonomo, Y. A., Norman, A. F., Collins, L., Ross, M., Dwyer, J. L., Perkins, D., & Sarris, J. J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1545915 · Cited by 4
Self-citationBlack, T. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1159843 · Cited by 3
Andión, Ó., Bouso, J. C., Sarris, J. J., Tófoli, L. F., Opaleye, E. S., & Perkins, D. (2025) · PLOS mental health. · doi:10.1371/journal.pmen.0000097 · Cited by 3
“…that same sense, participants’ previous anxiety disorder was the most significant predictor of experiencing any adverse effect from both the emotional-cognitive and psychotomimetic categories [6], a finding that was also observed in a study with regular religious ayahuasca ceremony attendees [80].”
InfluentialSelf-citationManaging Psychological Challenges in the Subacute (“Afterglow”) Window of Psychedelic Drug Effects
Evens, R., Uyar, A., & Majić, T. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_612 · Cited by 3
Camargos, G. S., de Faria, G. M., Lourenço, M., & Filho, G. M. D. A. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1726909 · Cited by 2
Haupt, M. J., Carra, S., Boehnke, K. F., & Aday, J. S. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111634 · Cited by 3
Halperin, D., On, T. B., Tadmor, N., Simon, A. M., Cherniak, A. D., & Simon, G. (2025) · Future Humanities · doi:10.1002/fhu2.70009 · Cited by 2
“…emotional distress, these experiences are sometimes subjectively perceived to be helpful or beneficial (Carbonaro et al. 2016; Evans et al. 2023; Johnstad 2021; Simonsson et al. 2023), at times even transformative in their potential to spark personal growth (Bouso et al. 2022; Bremler et al. 2023).”
Chwyl, C., Elvenes, O. S., Kleven, A. S. R., Kongshaug, E. W., Luoma, J. B., Pilecki, B. C., & Næss, E. T. (2025) · Research Square · doi:10.21203/rs.3.rs-6874539/v1 · Cited by 2
Oliver, C. R., Luke, D., Evans, J., Aday, J. S., Johnson, M., Lake, S., Kruger, D. J., Kevin, F. B., & Lucas, P. (2026) · Research Square · doi:10.21203/rs.3.rs-9304959/v1 · Cited by 2
“However, 88% of those who did experience adverse effects considered such mental health effects as part of a positive process of growth or integration 11 .”
Postránecká, Z., Lucký, M., Mravčík, V., & Páleníček, T. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00514 · Cited by 1
Soto-Angona, Ó., Rodríguez‐Urrutia, A., Ramos‐Quiroga, J. A., Álvarez-Bobo, Ó., Oña, G., Rosal, S. P., París-Pérez, J., & Wolff, M. (2025) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2025.100923 · Cited by 1
Psykologisk behandling av vedvarende vansker etter bruk av psykedelika
Holmøy, B., & Andersen, K. A. A. (2025) · Tidsskrift for Norsk psykologforening · doi:10.52734/qaow7353 · Cited by 1
Lowe, M. X., Darby, Q. A., Kalcheff-Korn, S., & Jackson, H. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2644858 · Cited by 2
Egger, K., Bozsak, R., Aicher, H., Sari, H., Poetzsch, S. N., Rominger, A., Martin-Soelch, C., Smallridge, J. W., Dornbierer, D., Quednow, B. B., et al. (2026) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x261454172 · Cited by 2
“14 Despite the burgeoning clinical interest in ayahuasca and its analogues, there is scant documentation of their effects on brain function.”
Self-citationThe DEA report on ayahuasca risks: “Science” in service of prohibition?
Labate, B. C., Ermakova, A. O., Sloshower, J., Coelho, N. L. G., Palhano-Fontes, F., Antunes, H. F., de Assis, G. L., Cavnar, C., de Araújo, D. B., & Ribeiro, S. T. G. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00279 · Cited by 1
Greene, S. L. (2025) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2024.12.002 · Cited by 1
Ayahuasca in the treatment of bipolar disorder with psychotic features–A retrospective case studyPreprint
Turkia, M. (2023) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/65se9 · Cited by 2
A força da espiritualidade na saúde: O uso da Ayahuasca
Andrade, K. C., Vanz, F., & Bellaver, E. H. (2023) · Seven Editora eBooks · doi:10.56238/ciesaudesv1-055
de Lima, V. M., & Marinho, M. G. S. M. D. C. (2023) · Revista Brasileira de História da Ciência · doi:10.53727/rbhc.v16i1.829
Kültürel Miras ile Uyuşturucu Madde Tartışmaları Arasında Ayahuasca
Şahin, N. (2023) · Kocatepe İslami İlimler Dergisi · doi:10.52637/kiid.1355099
Introduction to the EMBARK Approach
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0003
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0006
Bringing It Home and Carrying It Forward
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0009
Considerations Prior to Meeting With a Participant
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0005
INTRODUCTION: A New Approach for the Whole Person
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0001
Choosing Suggested Integration Goals
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0004
Working Within the EMBARK Domains Cheat Sheet
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0003
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0007
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0002
An Overview of Psychedelic-Assisted Therapy
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0002
Personal Care for the Therapist
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.005.0001
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0008
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.002.0004
EMBARK Mechanisms of Change in the Treatment of Depression
Brennan, B., & Belser, A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197762622.003.0004
Cornejo, G. S. E., Cárdenas, F. P., Torres, D., Valderrama, M., & Ettenberger, M. (2025) · Psychoactives · doi:10.3390/psychoactives4020009
Metadata
- Authors
- Bouso, J. C., Andión, Ó., Sarris, J. J., Scheidegger, M., Tófoli, L. F., Opaleye, E. S., Schubert, V., & Perkins, D.
- Affiliations
- Universidade de São Paulo (BR)
- The University of Melbourne (AU)
- University of Zurich (CH)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Universidade Federal de São Paulo (BR)
- Corresponding author
- Perkins, Daniel
- ORCID
- Venue
- PLOS Global Public Health
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-11-16
- Volume
- 2
- Issue
- 11
- Pages
- e0000438
- ISSN
- 2767-3375 (ISSN-L)
- PMC
- PMC10021266
- OpenAlex
- W4309139242
- Cited by
- 118
- References
- 70
- Citations by year
- 2026: 17 · 2025: 38 · 2024: 40 · 2023: 22 · 2022: 1
- FWCI
- 23.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLOS Global Public Health (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- ayahuasca, adverse effects, ayahuasca ceremonies, ritual use, mental health outcomes, physical health effects, vomiting, anxiety disorders, spiritual experience, benefits and risks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.